Zobrazeno 1 - 10
of 59
pro vyhledávání: '"M. Pamela Griffin"'
Autor:
Jerome Bouquet, David E. Tabor, Jonathan S. Silver, Varsha Nair, Andrey Tovchigrechko, M. Pamela Griffin, Mark T. Esser, Bret R. Sellman, Hong Jin
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-13 (2020)
Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by frequent exacerbation phenotypes independent of disease stage. Increasing evidence shows that the microbiota plays a role in disease progress
Externí odkaz:
https://doaj.org/article/b40782eaebb849488cb62f533a32979e
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 7, Pp 737-749 (2017)
Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is onl
Externí odkaz:
https://doaj.org/article/fef253ef6b8c43d79a943226e843a2fe
Autor:
Eric A F Simões, Shabir A Madhi, William J Muller, Victoria Atanasova, Miroslava Bosheva, Fernando Cabañas, Manuel Baca Cots, Joseph B Domachowske, Maria L Garcia-Garcia, Ineta Grantina, Kim A Nguyen, Heather J Zar, Anna Berglind, Celeste Cummings, M Pamela Griffin, Therese Takas, Yuan Yuan, Ulrika Wählby Hamrén, Amanda Leach, Tonya Villafana
Publikováno v:
The Lancet Child & Adolescent Health. 7:180-189
Autor:
Laura L, Hammitt, Ron, Dagan, Yuan, Yuan, Manuel, Baca Cots, Miroslava, Bosheva, Shabir A, Madhi, William J, Muller, Heather J, Zar, Dennis, Brooks, Amy, Grenham, Ulrika, Wählby Hamrén, Vaishali S, Mankad, Pin, Ren, Therese, Takas, Michael E, Abram, Amanda, Leach, M Pamela, Griffin, Tonya, Villafana, Jon, Heinrichs
Publikováno v:
New England Journal of Medicine. 386:837-846
BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and safety
Autor:
M Pamela, Griffin, Yuan, Yuan, Therese, Takas, Joseph B, Domachowske, Shabir A, Madhi, Paolo, Manzoni, Eric A F, Simões, Mark T, Esser, Anis A, Khan, Filip, Dubovsky, Tonya, Villafana, John P, DeVincenzo, Anne, Zomcik
Publikováno v:
New England Journal of Medicine. 383:415-425
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being devel
Autor:
William E. King, Waldemar A. Carlo, T. Michael O'Shea, Robert L. Schelonka, Charles Bauer, Karen D. Fairchild, M. Pamela Griffin, Jennifer Helderman, John Kattwinkel, Douglas E. Lake, J. Randall Moorman, Christina T. Navarrete, Myriam Peralta-Carcelen, Vivien Phillips
Publikováno v:
The Journal of pediatrics. 242
We hypothesized that a cumulative heart rate characteristics (HRC) index in real-time throughout the neonatal intensive care unit (NICU) hospitalization, alone or combined with birth demographics and clinical characteristics, can predict a composite
Autor:
Laura Hammitt, Ron Dagan, Yuan Yuan, Manuel Baca Cots, Miroslava Bosheva, Shabhir A Mahdi, William J Muller, Heather J Zar, Dennis Brooks, Amy Grenham, Ulrika Wählby Hamrén, Vaishali S Mankad, Pin Ren, Therese Takas, Jon Heinrichs, Amanda Leach, M Pamela Griffin, Tonya L Villafana
Publikováno v:
Open Forum Infectious Diseases
Background Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35
Autor:
M. Pamela Griffin, Jerome Bouquet, Varsha Nair, Andrey Tovchigrechko, David E. Tabor, Mark T. Esser, Hong Jin, Bret R. Sellman, Jonathan Silver
Publikováno v:
Respiratory research, 21:77
Respiratory Research, Vol 21, Iss 1, Pp 1-13 (2020)
Respiratory Research
Respiratory Research, Vol 21, Iss 1, Pp 1-13 (2020)
Respiratory Research
Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease characterized by frequent exacerbation phenotypes independent of disease stage. Increasing evidence shows that the microbiota plays a role in disease progression and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a70b534ffc668a4d382eea1b15b336
https://repository.publisso.de/resource/frl:6423645
https://repository.publisso.de/resource/frl:6423645
Publikováno v:
Expert Review of Vaccines. 16:737-749
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide and also causes significant disease in the elderly. Despite 60 years of RSV research and vaccine development, there is only one approved
Autor:
Eugene V. Millar, Kathryn M Jensen, Robert Weatherholtz, Katherine L. O'Brien, Hasan S. Jafri, Mathuram Santosham, Ruth A. Karron, Terramika Bellamy, Brian Harris, Genevieve A. Losonsky, Aruna Chandran, Lawrence H. Moulton, Raymond Reid, M. Pamela Griffin
Publikováno v:
The Lancet Infectious Diseases. 15:1398-1408
Summary Background Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children. We aimed to assess the safety and efficacy of an anti-RSV monoclonal antibody (motavizumab) in healthy term (≥36 weeks'